Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $3.3 million.

  • Taysha Gene Therapies' Share-based Compensation fell 214.48% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year increase of 953.18%. This contributed to the annual value of $13.1 million for FY2024, which is 6575.59% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Share-based Compensation stood at $3.3 million, which was down 214.48% from $3.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Share-based Compensation ranged from a high of $5.3 million in Q1 2022 and a low of $1.7 million during Q1 2023
  • In the last 4 years, Taysha Gene Therapies' Share-based Compensation had a median value of $3.3 million in 2025 and averaged $3.3 million.
  • Per our database at Business Quant, Taysha Gene Therapies' Share-based Compensation crashed by 6856.82% in 2023 and then skyrocketed by 9092.54% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Share-based Compensation stood at $4.1 million in 2022, then plummeted by 52.04% to $2.0 million in 2023, then soared by 63.41% to $3.2 million in 2024, then increased by 2.15% to $3.3 million in 2025.
  • Its Share-based Compensation was $3.3 million in Q3 2025, compared to $3.2 million in Q2 2025 and $3.3 million in Q1 2025.